Cargando…
Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed t...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610050/ https://www.ncbi.nlm.nih.gov/pubmed/33342194 http://dx.doi.org/10.4274/tjo.galenos.2020.38488 |
_version_ | 1783605121355087872 |
---|---|
author | Barış, Mine Esen Menteş, Jale Afrashi, Filiz Nalçaçı, Serhad Akkın, Cezmi |
author_facet | Barış, Mine Esen Menteş, Jale Afrashi, Filiz Nalçaçı, Serhad Akkın, Cezmi |
author_sort | Barış, Mine Esen |
collection | PubMed |
description | OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. RESULTS: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p<0.001) and 5 subgroups were identified. CONCLUSION: Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features. |
format | Online Article Text |
id | pubmed-7610050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-76100502020-11-13 Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration Barış, Mine Esen Menteş, Jale Afrashi, Filiz Nalçaçı, Serhad Akkın, Cezmi Turk J Ophthalmol Original Article OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. RESULTS: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p<0.001) and 5 subgroups were identified. CONCLUSION: Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features. Galenos Publishing 2020-10 2020-10-30 /pmc/articles/PMC7610050/ /pubmed/33342194 http://dx.doi.org/10.4274/tjo.galenos.2020.38488 Text en © Copyright 2020 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Barış, Mine Esen Menteş, Jale Afrashi, Filiz Nalçaçı, Serhad Akkın, Cezmi Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title | Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title_full | Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title_fullStr | Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title_full_unstemmed | Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title_short | Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration |
title_sort | subgroups and features of poor responders to anti-vascular endothelial growth factor treatment in eyes with neovascular age-related macular degeneration |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610050/ https://www.ncbi.nlm.nih.gov/pubmed/33342194 http://dx.doi.org/10.4274/tjo.galenos.2020.38488 |
work_keys_str_mv | AT barısmineesen subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration AT mentesjale subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration AT afrashifiliz subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration AT nalcacıserhad subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration AT akkıncezmi subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration |